Skip to main content
. 2022 Apr;13(2):478–487. doi: 10.21037/jgo-22-131

Table 2. Treatment-related adverse events.

Adverse events 1–2 grade, n (%) ≥≥3 grade, n (%)
Leucopenia 3 (15.0) 1 (5.0)
Neutropenia 3 (15.0) 0
Lymphopenia 2 (10.0) 0
Anemia 1 (5.0) 1 (5.0)
Increased transaminase 2 (10.0) 1 (5.0)
Alopecia 4 (20.0) 0
Constipation 2 (10.0) 0
Diarrhea 1 (5.0) 0
Fatigue 3 (15.0) 0
Nausea 4 (20.0) 0
Vomiting 3 (15.0) 0
Immune dermatitis 1 (5.0) 1 (5.0)
Immune pneumonitis 0 (0.0) 0 (0.0)